Latest Darbepoetin alfa Stories
EXTON, Pa., Sept. 28 /PRNewswire/ -- BioTrends Research Group, Inc.
EXTON, Pa., July 26 /PRNewswire/ -- BioTrends Research Group, Inc. recently published its TreatmentTrendsÂ®: US Nephrology Q2 2010 report.
THOUSAND OAKS, Calif., May 20 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that results from studies involving nine molecules in the Company's oncology portfolio will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4( )- 8, 2010 in Chicago. "Cancer is a complex disease that requires a comprehensive approach.
A new study helps dispel mounting confusion over the safety of blockbuster anemia drugs â€” erythropoiesis-stimulating agents â€” for people with kidney disease requiring dialysis, as federal regulators prepare to decide whether to impose additional restrictions on their use.
SILVER SPRING, Md., Feb 16 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs).
HORSHAM, Pa., Feb. 16 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. and Amgen Inc. today announced that the U.S.
THOUSAND OAKS, Calif., Feb. 16 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) and Centocor Ortho Biotech Products, L.P., today announced that the U.S.
EXTON, Pa., Jan. 6 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the availability of its TreatmentTrendsÂ®: US Nephrology, EU Nephrology, and Canadian Nephrology publications.
An international study authored by a UT Southwestern Medical Center researcher has concluded that the anemia drug darbepoetin alfa works no better than a placebo in several other applications previously thought to be promising.
NEW YORK, Dec.
- The governor of a province or people.